SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced it has launched TruSight® Tumor 15, a next-generation sequencing (NGS) panel designed to identify sequence variants in 15 genes commonly associated with marketed therapeutics. TruSight Tumor 15 is optimized for low input DNA from tissue preserved in formalin and paraffin.
Help employers find you! Check out all the jobs and post your resume.
